Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Dapagliflozin benefits liver disease patients

Written by | 12 Jun 2025

The type 2 diabetes treatment dapagliflozin appears to also benefit patients with liver disease, researcher reported on June 4, 2025 in The BMJ today. The findings suggest that treatment with… read more.

Farxiga (dapagliflozin) approved in the US for the treatment of paediatric type-2 diabetes – AstraZeneca

Written by | 27 Jun 2024

AstraZeneca’s Farxiga (dapagliflozin) has been approved by the FDA to improve glycaemic control in paediatric patients with type-2 diabetes (T2D) aged 10 years and older. The FDA approval… read more.

Dapagliflozin improves outcomes in heart failure among frail patients

Written by | 27 Apr 2022

Adjunctive dapagliflozin therapy appears to improve outcomes in heart failure patients without regard to frailty status at initiation of treatment. These findings appeared on April 26, 2022 in… read more.

Dapagliflozin shows efficacy in chronic kidney disease

Written by | 23 Nov 2020

Article written by Bruce Sylvester Patients with chronic kidney disease have achieved improved outcomes with dapagliflozin treatment, researchers reported on October 8, 2020 in the NEJM/New England Journal… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.